65,437 trials
Methamphetamine-dependence · Methamphetamine Abuse
Primary: Change in Plasma Methamphetamine (METH) Area Under the Curve (AUCinf) Resulting From METH Challenge Doses Following Single IV Doses of IXT-m200 — 1635; 1433; 1265; 1233…
Adverse Effect · Atherosclerosis, Coronary · Insulin Resistance Syndrome
Primary: Сardiovascular Death — 0; 0; 0; 0 Participants
Alopecia Areata
Primary: Number of Responders vs Non-Responders Using SALT Score — 9; 10 Participants
Astigmatism
Primary: Near Visual LogMAR Acuity — -0.10; -0.03 LogMAR
Tobacco Use Cessation
Primary: Number of Participants With Self-reported 7-day Abstinence From Smoking at 12 Weeks — 0; 1; 1; 4 Participants
Acute Coronary Syndrome · Depression
Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale
Chronic Venous Insufficiency
Primary: Vein Occlusion Rate — 29; 0; 0 limbs
Colon Cancer · Rectal Cancer · Ileostomy - Stoma
Primary: Number of Participants With Wound Occurrences — 0 Participants
Dental Caries
Primary: Predicted Peak Serum Silver Concentration (Cmax) — 17.8 ng/ml
COPD Exacerbation
Primary: Composite of COPD Hospital Readmission/Death Within 6 Month of Discharge — 1.34; 1.06; 0.88; 1.35 Hospitalizations/death — p=<.05
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
Spinal Cord Injuries
Primary: Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) — 212; 274; 393; NA Total LTPA min/week
Myelofibrosis
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Generalized Pustular Psoriasis
Primary: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1…
Asthma
Primary: Insurance Coverage — 11; 17; 1; 8 Participants